Sensibilidad in vitro de hongos miceliales de aislamientos clínicos en pacientes con cáncer en el Instituto Nacional de Cancerología ESE

Chavez, Jenny; Rivas, Pilar; Cortés, Jorge; Cuervo, Sonia; Sánchez, Ricardo; Parra, Claudia

doi:10.1016/S0123-9392(10)70129-6

Información del artículo

Resumen

Bibliografía

Descargar PDF

Estadísticas

Resumen

Introducción

la sensibilidad antifúngica in vitro en hongos filamentosos no ha tenido el mismo desarrollo que en levaduras. Se dispone de limitada información sobre la susceptibilidad en este tipo de aislamientos en Colombia.

Materiales y métodos

se determinó la actividad in vitro de fluconazol, voriconazol, itraconazol, anfotericina B y caspofungina mediante el método de E-Test, de los géneros Aspergillus (36 A. fumigatus, 12 A. flavus, 9 A. niger, 6 A. terreus, 4 A. nidulans y 1 A. versicolor) e hifomicetes hialinos (9 Fusarium sp., 2 Geotrichum sp. y 2 Paecilomyces sp.), provenientes en su mayoría de lavados broncoalveolares (30%) y biopsias pulmonares (36%); 9% provenían de hemocultivos.

Resultados

el perfil de resistencia general fue 28% para itraconazol, 15% para caspofungina, 14% para anfotericina B y 5% para voriconazol. En general, todos los aislamientos presentaron una sensibilidad disminuida para fluconazol e itraconazol. La mejor actividad farmacológica la presentaron voriconazol, caspofungina y anfotericina B. Fusarium sp. presentó una mayor actividad con el voriconazol. Se encontraron diferencias entre el tipo de micelio (Aspergillus vs no Aspergillus) y la susceptibilidad a voriconazol, anfotericina B y caspofungina.

Conclusión

en general, los antimicóticos disponibles para el tratamiento de infecciones por miceliales muestran una sensibilidad disminuida in vitro en relación con el género y la especie identificada.

Palabras clave:

pruebas de sensibilidad microbiana

pruebas antimicrobianas de difusión por disco

hongos

aspergillus

fusarium

agentes antifúngicos

resistencia a medicamentos

Abstract

Introduction

fungal susceptibility against micelial fungi has not been developed at the same pace as susceptibility against yeasts. Scarce information is available about that kind of isolates in Colombia.

Materials and methods

in vitro susceptibility against micelial isolates from patients with cancer was determined. The E-test method was used to find out susceptibility against fluconazole, voriconazole, itraconazole, amphotericin B, and caspofungin. Isolates of the genera Aspergillus (36 A. fumigatus, 12 A. flavus, 9 A. niger, 6 A. terreus, 4 A. nidulans and one A. versicolor isolate), Fusarium (n = 9), Geotrichum and Paecilomyces (n = 2 each one) obtained from patients with cancer were tested. These isolates were obtained from bronchoalveolar lavage (30%), pulmonary biopsies (36%) and bloodstream infections (9%).

Results

The general pattern of resistance was 28% against intraconazole, 15% against caspofungin, 14% against amphotericin B, and 5% against voriconazole. In general, susceptibility against fluconazole and itraconazole showed a diminishing trend. Voriconazole, caspofungin, and amphotericin B showed the best pharmacologic potency. Fusarium sp. presented a higher activity level against voriconazole. There were differences in the susceptibility against voriconazole, anphotericin B, and caspofungin depending on the type of micelial isolate (Aspergillus vs. Non- Aspergillus).

Conclusion

In general, the available antifungal treatments against mycelial fungi identified in the cancer center show diminished susceptibility.

Keyswords:

microbial sensitivity tests

disk diffusion antimicrobial tests

fungus drug sensitivity tests

aspergillus

fusarium

antifungal agents

Amphotericin B

Voriconazole

Itraconazole

El Texto completo está disponible en PDF

Referencias

[1.]

S. Ascioglu, J.H. Rex, B. de Pauw, J.E. Bennett, J. Bille, F. Crokaert, et al.

Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus.

Clin Infect Dis, 34 (2002), pp. 7-14

http://dx.doi.org/10.1086/323335 | Medline

[2.]

B. De Pauw, T.J. Walsh, J.P. Donnelly, D.A. Stevens, J.E. Edwards, T. Calandra, et al.

Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group.

Clin Infect Dis, 46 (2008), pp. 1813-1821

http://dx.doi.org/10.1086/588660 | Medline

[3.]

C. Lass-Flörl, S. Perkhofer, A. Mayr.

In vitro susceptibility testing in fungi: a global perspective on a variety of methods.

Mycoses, 53 (2010), pp. 1-11

Medline

[4.]

G. Forrest.

Role of antifungal susceptibility testing in patient management.

Curr Opin Infect Dis, 19 (2006), pp. 538-543

http://dx.doi.org/10.1097/QCO.0b013e328010682c | Medline

[5.]

A. Espinel-Ingroff.

Mechanisms of resistance to antifungal agents: Yeasts and filamentous fungi.

Rev iberoam Micol., 25 (2008), pp. 101-106

Medline

[6.]

A. Espinel-Ingroff, E. Canton, J. Peman.

Updates in Antifungal Susceptibility Testing of Filamentous Fungi.

Current Fungal Infection Reports, 3 (2009), pp. 133-141

[7.]

S. Arikan.

Current status of antifungal susceptibility testing methods.

Med Mycol., 45 (2007), pp. 569-587

http://dx.doi.org/10.1080/13693780701436794 | Medline

[8.]

Clinical and Laboratory Standards Institute. Reference method for broth dilution antifungal susceptibility testing of filamentous fungi. Approved Standard, edn 2; Document M38-A2. Wayne, PA: National Committee for Clinical Laboratory Standards; 2008.

[9.]

AB BIODISK. E-Test technical guide 4b: antifungal susceptibility testing of molds. Suiza. ABBIODISK.com; 2007.

[10.]

M.A. Pfaller, M. Castanheira, D.J. Diekema, S.A. Messer, G.J. Moet, R.N. Jones.

Comparison of European Committee on Antimicrobial Susceptibility Testing (EUCAST) and E-test methods with the CLSI broth microdilution method for echinocandin susceptibility testing of Candida species.

J Clin Microbiol, 48 (2010), pp. 1592-1599

http://dx.doi.org/10.1128/JCM.02445-09 | Medline

[11.]

A. Espinel-Ingroff.

Comparison of the E-test with the NCCLS M38-P Method for Antifungal Susceptibility Testing of Common and Emerging Pathogenic Filamentous Fungi.

J Clin Microbiol, 39 (2001), pp. 1360-1367

http://dx.doi.org/10.1128/JCM.39.4.1360-1367.2001 | Medline

[12.]

A. Espinel-Ingroff, A. Rezusta.

E-Test Method for Testing Susceptibilities of Aspergillus spp To the New Triazoles Voriconazole and Posaconazole and to Established Antifungal Agents: Comparison with NCCLS Broth Microdilution Method.

J Clin Microbiol, 40 (2002), pp. 2101-2107

Medline

[13.]

J.B. Pfaller, S.A. Messer, R.J. Hollis, D.J. Diekema, M.A. Pfaller.

In vitro susceptibility testing of Aspergillus spp.: comparison of Etest and reference microdilution methods for determining voriconazole and itraconazole MICs.

J Clin Microbiol, 41 (2003), pp. 1126-1129

Medline

[14.]

M.C. Serrano, M. Ramirez, D. Morilla, et al.

A comparative study of the disc diffusion method with the broth microdilution and Etest methods for voriconazole susceptibility testing of Aspergillus spp.

J Antimicrob Chemother, 53 (2004), pp. 739-742

http://dx.doi.org/10.1093/jac/dkh172 | Medline

[15.]

F. Sabatelli, R. Patel, P.A. Mann, C.A. Mendrick, C.C. Norris, R. Hare, et al.

In vitro Activities of Posaconazole, Fluconazole, Itraconazole Voriconazole, and Amphotericin B against a Large Collectionof Clinically Important Molds and Yeasts.

Antimicrob Agents Chemother, 50 (2006), pp. 2009-2015

http://dx.doi.org/10.1128/AAC.00163-06 | Medline

[16.]

S.A. Messer, D.J. Diekema, R.J. Hollis, L.B. Boyken, S. Tendolkar, J. Kroeger, et al.

Evaluation of disk diffusion and Etest compared to broth microdilution for antifungal susceptibility testing of posaconazole against clinical isolates of filamentous fungi.

J Clin Microbiol, 45 (2007), pp. 1322-1324

http://dx.doi.org/10.1128/JCM.02450-06 | Medline

[17.]

A. Espinel-Ingroff, B. Arthington-Skaggs, N. Iqbal, D. Ellis, M.A. Pfaller, S. Messer, et al.

Multicenter Evaluation of a New Disk Agar Diffusion Method for Susceptibility Testing of Filamentous Fungi with Voriconazole, Posaconazole, Itraconazole Amphotericin B, and Caspofungin.

J Clin Microbiol, 45 (2007), pp. 1811-1820

http://dx.doi.org/10.1128/JCM.00134-07 | Medline

[18.]

M.T. Durán, D. Velasco, D. Canle, R. Moure, R. Villanueva.

Susceptibilidad antifúngica de aislados de Candida spp. de hemocultivos en un periodo de cinco años (1997-2001).

Enferm Infecc Microbiol Clin, 21 (2003), pp. 488-492

Medline

[19.]

D.J. Diekema, S.A. Messer, R.J. Hollis, R.N. Jones, M.A. Pfaller.

Activities of caspofungin, itraconazole, posaconazole, ravuconazole, voriconazole, and amphotericin B against 448 recent clinical isolates of filamentous fungi.

J Clin Microbiol., 41 (2003), pp. 3623-3626

Medline

[20.]

M.A. Pfaller, L. Boyken, R.J. Hollis, J. Kroeger, A. Messer, S. Tendolkar, et al.

In vitro Susceptibility of Clinical Isolates of Aspergillus spp. To Anidulafungin, Caspofungin, and Micafungin: a Head-to-Head Comparison Using the CLSI M38-A2 Broth Microdilution Method.

J Clin Microbio, 47 (2009), pp. 3323-3325

[21.]

J.W. Baddley, K.A. Marr, D.R. Andes, T.J. Walsh, C.A. Kauffman, D.P. Kontoyiannis, et al.

Patterns of susceptibility of Aspergillus isolates recovered from patients enrolled in the Transplant-Associated Infection Surveillance Network.

J Clin Microbiol, 47 (2009), pp. 3271-3275

http://dx.doi.org/10.1128/JCM.00854-09 | Medline

[22.]

M.A. Pfaller, D.J. Diekema, M.A. Ghannoum, J.H. Rex, B.D. Alexander, D. Andes, et al.

Wild-Type MIC Distribution and Epidemiological Cutoff Values for Aspergillus fumigatus and Three Triazoles as Determined by the Clinical and Laboratory Standards Institute Broth Microdilution Methods.

J Clin Microbiol, 47 (2009), pp. 3142-3146

http://dx.doi.org/10.1128/JCM.00940-09 | Medline

[23.]

A.G. Prentice, A. Glasmacher, R.P. Hobson, S. Schey, R.A. Barnes, J.P. Donnelly, et al.

Guidelines on the management of invasive fungal infection during therapy for haematological malignancy.

British Committee for Standards in Haematology, (2007),

Indexada en:

Síguenos:

Indexada en:

Síguenos:

Suscríbase a la newsletter